A Multiple Enzyme‐Mimetic Platinum–Ruthenium Nanohybrid Prodrug Potentiates Chemo‐/Chemodynamic‐/Immuno‐Therapy of Hypoxic Tumors
Advanced Healthcare Materials · 2026
DOI: 10.1002/adhm.71484 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Huixi Yi und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Prodrugs, Platinum, Ruthenium, Antineoplastic Agents. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
Hypoxia in the tumor microenvironment (TME) is a hallmark of solid tumors and is tightly associated with the development of chemoresistance and immunosuppression, severely compromising the efficacy of mainstream clinical oncological treatments. Platinum‐based metallodrugs, especially oxaliplatin (Oxa), serve as first‐line chemotherapeutics in clinical practice. However, their clinical utility is greatly restricted by acquired drug resistance, insufficient tumor accumulation, and weak immunostimulatory capacity. Herein, we synthesize a platinum–ruthenium nanohybrid prodrug (denoted as PR) via self‐assembly, which integrates Oxa PR and ruthenium ions for synergistic chemo‐/chemodynamic‐/immunotherapy of hypoxic tumors. The PR nanohybrid possesses intrinsic multi‐enzyme activities (catalase, peroxidase, and glutathione peroxidase), enabling efficient oxygen generation, hydroxyl radical production, and glutathione depletion. These cascading events enhance chemosensitivity, trigger robust immunogenic cell death, and activate the cGAS‐STING signaling pathway. Furthermore, nanocatalytic modulation of the hypoxic TME alleviates hypoxia‐driven immunosuppression, downregulates PD‐L1 expression on cancer cells, and reinforces antitumor immune responses. In vitro and in vivo investigations demonstrate that PR nanohybrid exhibits superior anticancer efficacy over free Oxa and displays promising potential in combination with PD‐1 blockade therapy. These findings highlight the PR nanohybrid as a versatile TME‐modulating platform for hypoxic tumor treatment, offering a novel strategy to advance platinum‐based combination cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, China.
- School of Bioscience and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, China.
- College of Chemistry, Shandong Normal University, Jinan, China.
- National Engineering Research Center of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou, China.
ORCID-Profile: Jianliang Shen, Dong-Yang Zhang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
Zitieren
APA
Yi, H., Zheng, Y., Fu, N., Li, Q., Xue, S., Zhan, Z., Guo, L., Li, J., Yu, X., Shen, J., & Zhang, D. Y. (2026). A Multiple Enzyme‐Mimetic Platinum–Ruthenium Nanohybrid Prodrug Potentiates Chemo‐/Chemodynamic‐/Immuno‐Therapy of Hypoxic Tumors. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.71484
Vancouver
Yi H, Zheng Y, Fu N, Li Q, Xue S, Zhan Z, et al. A Multiple Enzyme‐Mimetic Platinum–Ruthenium Nanohybrid Prodrug Potentiates Chemo‐/Chemodynamic‐/Immuno‐Therapy of Hypoxic Tumors. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.71484
BibTeX
@article{Yi2026,
author = {Yi, Huixi and Zheng, Yue and Fu, Nannan and Li, Qiuhua and Xue, Shanshan and Zhan, Zhixiong and Guo, Liyou and Li, Jingyao and Yu, Xiyong and Shen, Jianliang and Zhang, Dong-Yang},
title = {A Multiple Enzyme‐Mimetic Platinum–Ruthenium Nanohybrid Prodrug Potentiates Chemo‐/Chemodynamic‐/Immuno‐Therapy of Hypoxic Tumors},
journal = {Advanced Healthcare Materials},
year = {2026},
doi = {10.1002/adhm.71484}
}
EUVIMED